CN106132442B - 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 - Google Patents

血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 Download PDF

Info

Publication number
CN106132442B
CN106132442B CN201580010172.XA CN201580010172A CN106132442B CN 106132442 B CN106132442 B CN 106132442B CN 201580010172 A CN201580010172 A CN 201580010172A CN 106132442 B CN106132442 B CN 106132442B
Authority
CN
China
Prior art keywords
antibody
antibodies
plasma kallikrein
binding
hae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580010172.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN106132442A (zh
Inventor
容强
丹尼尔·J·塞克斯顿
克里斯托弗·滕霍尔
乔恩·A·肯尼森
莱恩·福赛特
莱恩·伊尔罗比诺
约瑟夫·比登卡普
伯特·阿德尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd, Dyax Corp filed Critical Takeda Pharmaceutical Co Ltd
Priority to CN202310760869.5A priority Critical patent/CN116585468A/zh
Publication of CN106132442A publication Critical patent/CN106132442A/zh
Application granted granted Critical
Publication of CN106132442B publication Critical patent/CN106132442B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
    • C12Y207/03002—Creatine kinase (2.7.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580010172.XA 2014-01-21 2015-01-21 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 Active CN106132442B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310760869.5A CN116585468A (zh) 2014-01-21 2015-01-21 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461929716P 2014-01-21 2014-01-21
US61/929,716 2014-01-21
US201461944361P 2014-02-25 2014-02-25
US61/944,361 2014-02-25
US201462021397P 2014-07-07 2014-07-07
US62/021,397 2014-07-07
PCT/US2015/012212 WO2015112578A1 (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310760869.5A Division CN116585468A (zh) 2014-01-21 2015-01-21 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途

Publications (2)

Publication Number Publication Date
CN106132442A CN106132442A (zh) 2016-11-16
CN106132442B true CN106132442B (zh) 2023-07-14

Family

ID=53681890

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580010172.XA Active CN106132442B (zh) 2014-01-21 2015-01-21 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
CN202310760869.5A Pending CN116585468A (zh) 2014-01-21 2015-01-21 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310760869.5A Pending CN116585468A (zh) 2014-01-21 2015-01-21 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途

Country Status (18)

Country Link
US (2) US11084884B2 (enExample)
EP (2) EP3848057B1 (enExample)
JP (4) JP6845012B2 (enExample)
KR (3) KR102424183B1 (enExample)
CN (2) CN106132442B (enExample)
AU (3) AU2015209481C1 (enExample)
BR (1) BR112016016916B1 (enExample)
CA (1) CA2937329C (enExample)
DK (1) DK3096798T3 (enExample)
EA (1) EA038532B1 (enExample)
ES (1) ES2856076T3 (enExample)
IL (3) IL246864B (enExample)
MX (2) MX387753B (enExample)
NZ (2) NZ723369A (enExample)
PL (1) PL3096798T3 (enExample)
PT (1) PT3096798T (enExample)
WO (1) WO2015112578A1 (enExample)
ZA (2) ZA201605342B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181419T1 (hr) 2010-01-06 2018-11-16 Dyax Corp. Plazma kalikrein vezni proteini
IL269565B2 (en) * 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
JP6444315B2 (ja) 2013-01-20 2018-12-26 ダイアックス コーポレーション ブラジキニン媒介障害の評価および治療
CA3208188A1 (en) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
KR102665705B1 (ko) 2013-10-21 2024-05-14 다케다 파머수티컬 컴패니 리미티드 자가면역 질환의 진단 및 치료
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
CN106132442B (zh) 2014-01-21 2023-07-14 武田药品工业株式会社 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
AU2016243160B2 (en) * 2015-03-30 2022-02-24 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
EP3365685B1 (en) 2015-10-19 2020-11-25 Dyax Corp. Immunoassay to detect cleaved high molecular weight kininogen
WO2017100679A1 (en) * 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2018053260A1 (en) 2016-09-16 2018-03-22 Dyax Corp. Rna biomarkers for hereditary angioedema
AU2017325983B2 (en) * 2016-09-16 2023-12-07 Takeda Pharmaceutical Company Limited Protein biomarkers for diseases associated with the contact activation system
WO2019079496A2 (en) * 2017-10-18 2019-04-25 Regenxbio, Inc. FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION
JP7360716B2 (ja) 2017-12-01 2023-10-13 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
EP3718572B1 (en) 2017-12-01 2024-07-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use
JP7261494B2 (ja) 2017-12-01 2023-04-20 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
EP3719128B1 (en) 2017-12-01 2025-01-15 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof
JP7436030B2 (ja) 2017-12-29 2024-02-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 複合体及びその調製方法と使用
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
TW202100561A (zh) * 2019-03-14 2021-01-01 美商戴氏公司 血漿胰舒血管素抑制劑及其於治療遺傳性血管水腫發作的用途
CN118256498A (zh) 2019-05-22 2024-06-28 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
EP3992290A4 (en) * 2019-05-24 2023-11-15 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
CN101801406A (zh) * 2007-07-20 2010-08-11 基因塞斯投资有限公司 用于治疗淀粉样蛋白相关疾病的组织激肽释放酶
CA3168591A1 (en) * 2010-01-06 2011-07-14 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
CN102307594A (zh) * 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0296171A4 (en) 1986-03-03 1989-11-07 Brigham & Womens Hospital ASSESSMENT PROCEDURE FOR NEPHROTOXICITY.
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE69533472T2 (de) 1994-01-11 2006-01-12 Dyax Corp., Cambridge Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
PT1941867E (pt) 2002-06-07 2012-02-16 Dyax Corp Polipeptídeo contendo um domínio kunitz modificado
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1674480A4 (en) 2003-09-04 2007-06-20 Riken ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION
WO2005075665A2 (en) 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
WO2006017538A2 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
SI2374472T1 (sl) 2006-03-16 2018-11-30 Dyax Corp., Sestavki in postopki za zdravljenje oftalmoloških motenj
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
JP2010536883A (ja) 2007-08-23 2010-12-02 ジェンザイム・コーポレーション カリクレイン阻害剤を用いた治療
EP2313109A2 (en) 2008-07-02 2011-04-27 Emergent Product Development Seattle, LLC Il6 immunotherapeutics
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
IL269565B2 (en) * 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
LT2704742T (lt) 2011-05-02 2017-10-25 Millennium Pharmaceuticals, Inc. Anti-alfa4beta7 antikūno kompozicija
AU2013221635B2 (en) 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
KR102209796B1 (ko) 2013-01-20 2021-01-29 다이액스 코포레이션 pKal 매개 장애의 평가, 검정 및 치료
JP6444315B2 (ja) 2013-01-20 2018-12-26 ダイアックス コーポレーション ブラジキニン媒介障害の評価および治療
CA3208188A1 (en) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
CN106132442B (zh) 2014-01-21 2023-07-14 武田药品工业株式会社 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
AU2016243160B2 (en) 2015-03-30 2022-02-24 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
KR20250030022A (ko) * 2016-09-16 2025-03-05 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 대사물질 바이오마커
EP3678551B1 (en) 2017-09-05 2023-06-28 Sanolla Ltd Electronic stethoscope with enhanced features
BR112021003789A2 (pt) 2018-08-30 2021-05-18 Dyax Corp. método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
TW202100561A (zh) 2019-03-14 2021-01-01 美商戴氏公司 血漿胰舒血管素抑制劑及其於治療遺傳性血管水腫發作的用途
KR20220128379A (ko) 2020-01-13 2022-09-20 다케다 파머수티컬 컴패니 리미티드 소아 유전성 혈관부종 발작을 치료하기 위한 혈장 칼리크레인 억제제 및 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
CN101801406A (zh) * 2007-07-20 2010-08-11 基因塞斯投资有限公司 用于治疗淀粉样蛋白相关疾病的组织激肽释放酶
CN102307594A (zh) * 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
CA3168591A1 (en) * 2010-01-06 2011-07-14 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
遗传性血管性水肿的治疗;汤蕊;张宏誉;;中华临床免疫和变态反应杂志(第04期);全文 *
遗传性血管性水肿的研究进展;江建雄;郑敏;;国际皮肤性病学杂志(第03期);全文 *

Also Published As

Publication number Publication date
JP7164502B2 (ja) 2022-11-01
KR102424183B1 (ko) 2022-07-26
BR112016016916A2 (pt) 2018-01-23
DK3096798T3 (da) 2021-03-01
JP2017503820A (ja) 2017-02-02
KR20240033156A (ko) 2024-03-12
US11084884B2 (en) 2021-08-10
JP6845012B2 (ja) 2021-03-17
PL3096798T3 (pl) 2021-07-26
AU2015209481B2 (en) 2020-07-30
AU2020244370B2 (en) 2024-03-07
CA2937329A1 (en) 2015-07-30
KR20240049627A (ko) 2024-04-16
IL278062A (en) 2020-11-30
AU2015209481C1 (en) 2020-10-29
KR20220107077A (ko) 2022-08-01
WO2015112578A1 (en) 2015-07-30
IL263669A (en) 2019-01-31
EP3096798A4 (en) 2017-08-23
AU2024203436A1 (en) 2024-06-13
BR112016016916B1 (pt) 2023-12-19
IL278062B (en) 2022-06-01
ZA201605342B (en) 2020-11-25
AU2020244370A1 (en) 2020-10-29
MX387753B (es) 2025-03-18
ES2856076T3 (es) 2021-09-27
NZ761006A (en) 2023-04-28
CN116585468A (zh) 2023-08-15
AU2015209481A1 (en) 2016-08-25
EA038532B1 (ru) 2021-09-10
NZ723369A (en) 2022-12-23
US12384854B2 (en) 2025-08-12
MX2016009428A (es) 2017-04-13
JP2020002171A (ja) 2020-01-09
JP2023015087A (ja) 2023-01-31
CN106132442A (zh) 2016-11-16
MX2021013665A (es) 2021-12-10
JP2024170495A (ja) 2024-12-10
IL246864B (en) 2018-12-31
EP3096798B1 (en) 2020-11-25
ZA202004653B (en) 2022-01-26
KR20160122169A (ko) 2016-10-21
US20170002094A1 (en) 2017-01-05
US20210087293A1 (en) 2021-03-25
IL263669B (en) 2020-10-29
CA2937329C (en) 2022-05-31
PT3096798T (pt) 2021-02-25
EA201691470A1 (ru) 2016-12-30
EP3848057A1 (en) 2021-07-14
EP3096798A1 (en) 2016-11-30
EP3848057B1 (en) 2025-12-10
BR112016016916A8 (pt) 2018-05-02

Similar Documents

Publication Publication Date Title
CN106132442B (zh) 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
JP2023130442A (ja) 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用
JP7585193B2 (ja) 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
WO2021146160A1 (en) Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
KR102903403B1 (ko) 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
HK40057855A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Rong Qiang

Inventor after: Sexton Daniel J.

Inventor after: Tenhoor Christopher

Inventor after: A - Jon Kennison

Inventor after: Ryan Forsythe

Inventor after: Ryan Ilrobino

Inventor after: Joseph Bidenkap

Inventor after: Burt Adelman

Inventor before: Rong Qiang

Inventor before: Sexton Daniel J.

Inventor before: Tenhoor Christopher

Inventor before: A - Jon Kennison

Inventor before: Ryan Forsythe

Inventor before: Ryan Larobino

Inventor before: Joseph Bidenkap

Inventor before: Burt Adelman

COR Change of bibliographic data
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210611

Address after: 1-1, sidingmu, xiudaocho, Central District, Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: DYAX Corp.

GR01 Patent grant
GR01 Patent grant